Novartis AG faces major patent expiries but is buying pipeline assets to sustain growth. Click for this NVS update.

Why Novartis Stock Is On Investors’ Radar Novartis (SWX:NOVN) has attracted attention after recent share moves, with the ...

Novartis announced late Monday that the U.S. Food and Drug Administration (FDA) approved its Itvisma for certain forms of spinal muscular atrophy (SMA). The healthcare company didn't hesitate to ...

Novartis AG (NYSE:NVS) is one of the best pharma stocks to invest in now. Novartis AG (NYSE:NVS) announced on March 29 the final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® in ...

Swiss pharmaceutical group Novartis (NYSE:NVS) announced on Friday that it has reached an agreement to acquire ...

The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than ...

Editor’s Note: The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” mentioned in the original title. Swiss pharmaceutical giant ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Novartis (NVS) been one of those stocks this year? A quick ...

It earned FDA approval for a spinal muscular atrophy drug. Novartis announced late Monday that the U.S. Food and Drug Administration (FDA) approved its Itvisma for certain forms of spinal muscular ...